UK-based regenerative medicine company Regenerys has announced the acquisition of Altrika from its parent company Ilika.

Altrika, based in Sheffield, South Yorkshire, UK, supplies its cell-based skin regeneration therapies, Myskin and Cryoskin, for the treatment of severe burns and chronic wounds.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The revenue-generating company also provides bio-processing and bio-banking services to third parties developing advanced cell therapies.

Under the terms of the acquisition, Regenerys will take on all employees and assets, and Altrika’s Sheffield site will continue to operate.

"Under the terms of the acquisition, Regenerys will take on all employees and assets, and Altrika’s Sheffield site will continue to operate."

The acquisition provides Regenerys with necessary quality systems and licenses to operate from the Human Tissue Authority (HTA) and Medicines and Health products Regulatory Agency (MHRA), in addition to qualified scientific personnel to expand its cell bio-processing and bio-banking projects.

See Also:

Regenerys chairman Dr Bill Mason said the acquisition marks an important development in the company’s profile as a regenerative medicine business.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We are committed to providing innovative solutions to both patients and our customers for the natural regeneration of skin, tissue and organs using their own tissue," Mason said.

"This acquisition will enable us to build on our work in the area of breast reconstruction and cosmetic applications using adipose tissue, and extend our reach to the treatment of serious burns and chronic wounds.

"We are particularly pleased to be able to acquire Altrika and their talented scientific staff which will bring a very high level of expertise and quality to our business."